Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Apitegromab phase 3 trial in later-onset spinal muscular atrophy on nusinersen or risdiplam
NL-OMON51312Phase 3Completed
- Sponsor
- Scholar Rock
- Start
- Jul 2022
- Modality
- Monoclonal Antibodies → Antibody-Based Therapeutics
- Countries
- 1
01
Overview
Phase 3, randomised, double-blind trial of apitegromab in spinal muscular atrophy (SMA), spinal muscular atrophy type 2 (SMA2) and Spinal muscular atrophy type 3 (SMA3), sponsored by Scholar Rock. Started Jul 2022; status: completed.
02
Drugs
apitegromab
03
Conditions
spinal muscular atrophy (SMA)spinal muscular atrophy type 2 (SMA2)Spinal muscular atrophy type 3 (SMA3)
Beyond the preview
Go deeper on NL-OMON51312.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NL-OMON51312.